Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Charcoal experiment to reverse blood thinners halted before it began

NCT ID NCT02969746

Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to see if taking activated charcoal could help clear certain blood thinners (rivaroxaban, apixaban) faster in patients needing an urgent procedure. It planned to enroll 140 adults and measure how quickly the drug left their blood. However, the trial was withdrawn before any participants were enrolled, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Activated charcoal

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Started

Jul 2014

Finished

Sep 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients under direct oral anticoagulant treatment (Apixaban, Rivaroxaban or Dabigatran) * Age ≥18 years; * Clinical condition needing a surgery or invasive procedure ( lumbar puncture, biopsy...), needing anticoagulant treatment interruption and intervention to be postponed * Signed informed consent Exclusion Criteria: * Urgent immediate surgery without any possibility to wait for 24 hours * contraindication for receiving oral treatment * Active uncontrolled bleeding or bleeding in critical organ * Hemodynamic instability, shock * Known anticoagulant concentration \< 50ng/mL * drug intoxication * Fructose intolerance, glucose and galactose malabsorption syndrome, sucrase-isomaltase deficit * Treated epileptic disease * Pregnant or breast feeding * Patient under guardianship * No insurance cover * Patient unable to give his consent * Participation to another therapeutic trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anticoagulants; circulating, hemorrhagic disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anthrax infection hemorrhagic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anticoagulants; circulating, hemorrhagic disorder

Contacts and locations

Locations

  • CH Le MANS

    Le Mans, 72000, France

  • CHU Clermont-ferrand

    Cléron, 63000, France

  • CHU de Poitiers

    Poitiers, 86000, France

  • CHU de St Etienne

    Saint-Etienne, 42000, France

  • Chu Angers

    Angers, 49000, France

  • Chu Angers

    Angers, 49933, France